AlphAIAlphAI — Financial news for AI agents
manufacturingchemist.comOCT 125 min read$TEVA

Teva wins FDA approval for once-monthly olanzapine injection

Teva Pharmaceuticals received FDA approval for WELTRUZA, a once-monthly olanzapine injection for schizophrenia. Developed with Medincell's SteadyTeq technology, it requires no loading doses or post-injection monitoring. Teva plans a US launch in three strengths. The approval follows positive Phase III trial results, showing symptom improvements and a safety profile consistent with oral olanzapine. Medincell may earn royalties and milestone payments.

Original reporting
manufacturingchemist.com
Published Oct 12, 2026, 2:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva wins FDA approval for once-monthly olanzapine injection — source image
Source · manufacturingchemist.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The FDA approval is a direct de-risking event for Teva’s schizophrenia product pipeline, supported by Phase III SOLARIS efficacy and a safety profile consistent with oral olanzapine.

02

Market read

Traders can update Teva’s commercialization outlook for a differentiated LAI antipsychotic following a primary FDA approval and stated launch plan.

03

What to watch

The article does not quantify expected sales, competitive positioning versus existing olanzapine LAIs, or launch readiness metrics, which may temper immediate valuation response.

Relevance 7/10Novelty 8/10Timing: launch planned in the coming weeks after the 9 Oct FDA approval

Background

WELTRUZA is an extended-release, once-monthly subcutaneous olanzapine LAI using Medincell’s SteadyTeq copolymer technology.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva received FDA approval for WELTRUZA, a once-monthly olanzapine injection, and plans US launch in coming weeks.

Expected impact

Likely positive bias as traders price in incremental sales potential and reduced uncertainty versus pre-approval timelines.

Evidence & confidence

The article is a primary regulatory approval and includes launch timing and dosing strengths, which are direct catalysts for commercialization expectations.

Market effects

Sector

Reinforces demand for long-acting injectable (LAI) antipsychotics and may support sentiment toward LAI delivery-platform economics.

Regional

US FDA approval can shift expectations for US schizophrenia treatment competition and payer formulary discussions.

Global

Worldwide royalty and milestone structure highlights cross-border monetization potential for LAI platforms and partners.

Counterpoint

What could challenge this read

Approval does not guarantee uptake; payer coverage, clinician adoption, and manufacturing ramp could limit near-term sales impact.

Key entities

  • company
    Teva Pharmaceuticals

    US FDA-approved WELTRUZA (olanzapine) once-monthly injectable, planned US launch in coming weeks.

  • drug
    WELTRUZA

    Extended-release injectable suspension of olanzapine for adults with schizophrenia.

  • company
    Medincell

    Technology provider (SteadyTeq) eligible for mid- to high-single-digit royalties and up to $112m in milestones.

Read at source← All news

StoryFDA approves Teva’s once‑monthly subcutaneous olanzapine injection Weltruza

Also covered by

4 outlets

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min
OCT 12
$TEVAHigh

Morning Rounds: October 5-12

FDA approved Teva's Weltruza, a once-monthly olanzapine injection for schizophrenia, based on phase 3 trial results. Motivista's CT-155, a digital therapeutic, received clearance for negative schizophrenia symptoms. Neurosterix's NTX-253 completed phase 1 and will enter phase 2. Newron's evenamide faces a US trial hold due to 4 deaths in studies.

psychiatrictimes.com2 min